|
|
 |
|
Viewing report
|
|
 |
 |
Next Generation Drugs: Acceleration Through Innovation
Business Insights, March 2002
The pharmaceutical industry is now immersed in a wave of technological innovation to help accelerate drug discovery and development. However, selecting the most beneficial technological systems to reduce discovery and development timelines involves due consideration of a company''s R&D focus, pipeline commitments, synergies to enhance R&D programmes, and analysis of risk and competition. Next Generation Drugs: Acceleration through innovation is a new management report examining the technological innovations that are being employed by the pharmaceutical majors to expedite discovery research and R&D. Key areas of review include genomics, proteomics, pharmacogenomics, bioinformatics, and cheminformatics in addition to other key enabling high technology discovery and development platforms. This new report also reviews how companies are accelerating discovery through strategic collaborations, enhancement of in-house expertise, and by focusing on specific diseases or small molecules to optimize their future business plans.
Customers who bought this item also bought
Biomed Outsourcing Report: An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
Bio/Pharma R&D Statistical Sourcebook 2008/2009
Virtual Pharma - The Radical Route to Success
Advances in Lab-on-Chip and Microfluidics Technologies for Drug Discovery and Clinical Diagnostics
R&D Strategies: Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D
Addressing Pharma�s R&D Productivity Crisis: Technological and Strategic Initiatives to Improve Core Drug Discovery Capabilities
The Drug Discovery Marketplace
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan
Biomarkers 2008
Fueling the Drug Discovery Engine: Biotech Investment and Business Trends
Key Alliances and Partnerships in the World Drug Discovery Industry
|
 |
|
|